Hypotheses statement
We hypothesize that identifying genes which have been reported as differentially expressed in MS in several independent studies can expose pathways involved in MS pathogenesis.
Description of study outcome(s) Differential gene expression between MS patients and non-MS controls in peripheral blood cells.
Type of exposure or intervention used Multiple sclerosis patients were compared to non-MS controls.
Type of study designs used Microarray based gene expression studies.
Study population
Most patients had relapsing-remitting MS (both during relapse and in remission), but also progressive patients were included in some studies. Method of addressing articles published in languages other than English
SEARCH STRATEGY
The search did not produce any non-English records, which based on title and/or abstract would have been potentially eligible for our review.
Method of handling abstracts and unpublished studies NA Description of any contact with authors E-mail with corresponding authors.
METHODS
Description of relevance of appropriateness of studies assambled for assessing the hypothesis to be tested
The included studies can not be considered directly comparable due to differences in patients, cell populations, platforms and analyses methods. However, all included studies were conducted in cells from peripheral blood and identified genes in which expression levels were different in patients versus controls.
Rationale for the selection and coding of data
We extracted provided gene symbols/identifiers/descriptions for genes reported to show differential expression in MS. In addition, we recorded whether the gene showed increased or decreased expression in MS.
Documentation of how data were classified and coded (eg, multiple raters, blinding, and interrater reliability)
All data was extracted from the original publications by AK.
Assessment of confounding (eg, comparability of cases and controls in studies where appropriate)
Gender may have been a confounding factor in some of the studies: in the studies by Achiron et al. and Mandel et al. (these were treated as a single study) the ratio of females/males was higher in MS patients than in controls, while in the study by Bomprezzi et al. the reverse was true. In addition, the cases and controls were not gender-matched in the study by Arthur et al., but they conducted an analyses to identify genes which may have been affected by gender. However, because our analyses relied on genes which had been identified in at least two studies, potential confounding in few individual studies is unlikely to have had a major impact on our overall findings.
Finally, cases and controls were not age-matched in our unpublished experiment. Although again we believe that this is unlikely to have had a major impact on our overall observations, we re-ran the pathway analyses after excluding genes identified in our study and showed that the most interesting pathways were unaffected.
Assessment of study quality, including blinding of quality assessors, stratification or regression on possible predictors of study results
It is difficult to assess the quality of studies without raw data. However, all studies were published in peer-reviewed journals and had been conducted according to recommended protocols.
Assessment of heterogeneity NA
Description of statistical methods (eg, complete description of fixed or random effects models, justification of whether the chosen models account for predictors of study results, does-response models, or cumulative meta-analysis) in sufficient detail to be replicated P-values or fold differences in expression between cases and controls were not available for all studies. Even if these had been available, they could not have been considered comparable given the differences in platforms and samples. We therefore only used binary information (increased/decreased expression in MS) and counted the number of studies where a gene had been reported to be up/downregulated.
Provision of appropriate tables and graphics
See Table 1 and Figure 1 .
RESULTS
Graphic summarizing individual study estimates and overall estimate NA. Number of genes reported in each study is given in Table 1 . Some of the studies did not provide full lists of identified genes and our results are therefore to some extent affected by reporting bias. The true number of genes identified in at least two studies is therefore likely to be larger than observed.
Justification for exclusion (eg, exclusion of nonEnglish-language citations)
We decided to exclude studies with less than 10 cases or controls. While this is an arbitrary threshold, it is likely that the power of studies with <10 subjects/group for detecting true signals is very limited. In fact, in a complex disease like MS it is likely that tens or hundreds of cases will be required, depending on the heterogeneity of the cell population. Unfortunately, only a couple of such large studies have been conducted, and we therefore had to apply a more moderate criteria.
Assessment of quality of included studies
It is difficult to assess the quality of included studies without raw data. However, all studies had been published in peer-reviewed journals and had been conducted according to recommended protocols.
CONCLUSIONS

Consideration of alternative explanations for observed results
Given that the included studies were conducted in relatively heterogeneous cell populations, the identified genes may reflect differences in fractions of different immune cell populations in MS rather than truly differential activity of gene expression.
Generalization of the conclusions (ie, appropriate for the data presented and within the domain of the literature review)
It is likely that our findings of very poor overlap between expression studies apply to those conducted in many other complex traits.
Guidelines for future research Further expression studies in larger samples and less heterogeneous cell populations will be required in order to increase the power of detecting differentially expressed in MS. 
